Cloudflare upgraded, Marvell downgraded: Wall Street's top analyst calls
TRex Bio, Inc. TRXB
$12.92
▼ -4.93%
($-0.67)
⬇️ Below Yest. Low
Open
$13.55
Prev Close
$13.59
Day Range
$12.90 – $14.01
52W Range
$12.50 – $16.56
Market Cap
$372.99M
Beta
0.74
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-10-09 |
| Website | trex.bio ↗ |
| Phone | 16505675582 |
| Shares Out. | 27,445,682 |
About TRex Bio, Inc.
Trex Bio Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
TRex Bio, Inc. is a publicly traded company under the ticker symbol TRXB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📰 Latest News for TRXB
Evercore ISI Group Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $28
This X-Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
JP Morgan Initiates Coverage On Trex Bio with Overweight Rating, Announces Price Target of $20
Cantor Fitzgerald Initiates Coverage On Trex Bio with Overweight Rating
Stifel Initiates Coverage On Trex Bio with Buy Rating, Announces Price Target of $39
Wedbush Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $30
Apple Leads Packed Earnings Calendar As Investors Eye Tech, Pharma Results